SEC-sourced researchBeta
PBYI
PUMA BIOTECHNOLOGY, INC.
Company comparison ↗
Data passport
- CIK
- 0001401667
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Sep 16, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 235,637,000.0000 | Feb 26, 2026 |
| December 2024 | 230,468,000.0000 | Feb 26, 2026 |
| December 2025 | 228,371,000.0000 | Feb 26, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 228,371,000.0000 | 31,111,000.0000 | 41,802,000.0000 | 216,302,000.0000 | 85,962,000.0000 | Feb 26, 2026 |
| December 2024 | 230,468,000.0000 | 30,278,000.0000 | 38,918,000.0000 | 213,333,000.0000 | 121,208,000.0000 | Feb 26, 2026 |
| December 2023 | 235,637,000.0000 | 21,591,000.0000 | 27,009,000.0000 | — | — | Feb 26, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $228.37M | December 2025 | Feb 26, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $230.47M | December 2024 | Feb 26, 2026 | 10-K |
| Net incomeNetIncomeLoss | $31.11M | December 2025 | Feb 26, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $41.8M | December 2025 | Feb 26, 2026 | 10-K |
| Total assetsAssets | $216.3M | December 2025 | Feb 26, 2026 | 10-K |
| Total liabilitiesLiabilities | $85.96M | December 2025 | Feb 26, 2026 | 10-K |